A psychiatric medication system in the form of a pill with a built-in digital tracking device gained approval from the US Food and Drug Administration on Monday. 
Abilify MyCite, a form of aripiprazole and a first-of-its-kind product, has an embedded ingestible sensor that records when the medication is taken. Made by Japan-based Otsuka Pharmaceutical Co., the medication system is intended to treat schizophrenia, bipolar I disorder and depression in adults. Abilify without sensor technology was first approved to treat schizophrenia in 2002.
Schizophrenia, a psychotic disorder, includes symptoms of delusions and hallucinations. Bipolar patients may experience alternating episodes of mania and depression, a persistent sadness.
